|
2.6 Etiologie - Environnement
|
|
|
Australian Cancer Council calls for review of ‘Round-up’ — Expert Reaction [Science Media Centre]
|
|
|
|
|
|
“Since
the last Australian review, glyphosate has been reviewed by a number of
other jurisdictions, with mixed findings. I conclude that, if
glyphosate is a carcinogen, it’s a pretty weak one. so its impacts are
hard to distinguish from those of other factors that might lead to
cancer. APVMA would be wise to conduct a review, reminding us of those
overseas findings, reviewing the most recent literature, and evaluating
the risks to Australian users, consumers and wildlife.”
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
The clinical code-breakers [Nature]
|
|
|
|
|
|
And
unlike hereditary disorders, in which mutations are present throughout
the body, tumours can be highly heterogeneous, with cancerous and
healthy cells intermixed, and extensive genetic variation even within a
tumour. This means that more sequencing reads must be obtained for a
given region to confirm that a variant is real, and that bumps up the
cost.
|
|
|
|
|
|
|
5. Traitements
|
|
|
Studying Drug Safety in the Real World [JAMA Internal Medicine]
|
|
|
|
|
|
For
these reasons and others, real-world outcomes with a drug may not
mirror those of the randomized clinical trials that brought it to
market. If you want to know what a drug actually does in the real world,
you need to study it in the real world. That, however, is easier said
than done.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
New approach explored to treat childhood leukemia [UW Medicine]
|
|
|
|
|
|
Horwitz
and his team found that PAX2, which is normally activated by salt
levels in the kidney, can similarly be switched on by adjusting salt
concentrations for leukemia cells, a revelation that is leading to a new
line of inquiry into the physiology of B-Cells and perhaps, new clues
about how ALL begins and how it can be stopped.
|
|
|
|
|
|
|
Hypoxia compound disrupts cancer cell metabolism [Crick Institute]
|
|
|
|
|
|
The
team discovered that MCT2 transports a derivative of DMOG inside cancer
cells, where it disrupts multiple enzymes in glutamine metabolism – an
essential amino acid for cancer cell survival. The findings, published
in Nature Chemical Biology suggest that MCT2 expression could be used to
predict which cancers are likely to respond to DMOG, or similar
compounds.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round [FierceBiotech]
|
|
|
|
|
|
Sitryx
is built upon research into the role metabolic pathways play in the
function of immune cells and, by extension, the development of cancers
and autoimmune diseases. By designing drugs that act on these pathways,
Sitryx and its transatlantic syndicate of founding scientists think they
can correct immune cell function and stop tumor growth.
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.6 ESMO
|
|
|
|
|
|
|
|
5.6.9 ESMO - Col de l'utérus
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.1 Observation
|
|
|
|
Cancer disparities: It’s money that matters (along with a lot of other things) [Respectful Insolence]
|
|
|
|
|
|
There
are biological differences among populations, socioeconomic
differences, differences in environmental exposures, differences in
health behaviors, differences in so many things, that it’s hard to tell
how much of which disparity is likely to be caused or mediated by what
factor. Thus designing and implementing strategies to reduce these
disparities are among the most difficult challenges cancer professionals
face.
|
|
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|